Free Trial

ANI Pharmaceuticals (ANIP) Competitors

ANI Pharmaceuticals logo
$64.96 -1.14 (-1.72%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$64.94 -0.02 (-0.04%)
As of 07/11/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ANIP vs. ADMA, ANVS, LNTH, TLX, AXSM, AKRO, PCVX, KRYS, RYTM, and CYTK

Should you be buying ANI Pharmaceuticals stock or one of its competitors? The main competitors of ANI Pharmaceuticals include ADMA Biologics (ADMA), Annovis Bio (ANVS), Lantheus (LNTH), Telix Pharmaceuticals (TLX), Axsome Therapeutics (AXSM), Akero Therapeutics (AKRO), Vaxcyte (PCVX), Krystal Biotech (KRYS), Rhythm Pharmaceuticals (RYTM), and Cytokinetics (CYTK). These companies are all part of the "pharmaceutical products" industry.

ANI Pharmaceuticals vs. Its Competitors

ANI Pharmaceuticals (NASDAQ:ANIP) and ADMA Biologics (NASDAQ:ADMA) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation, analyst recommendations and media sentiment.

ANI Pharmaceuticals has a beta of 0.57, suggesting that its share price is 43% less volatile than the S&P 500. Comparatively, ADMA Biologics has a beta of 0.43, suggesting that its share price is 57% less volatile than the S&P 500.

In the previous week, ANI Pharmaceuticals had 2 more articles in the media than ADMA Biologics. MarketBeat recorded 6 mentions for ANI Pharmaceuticals and 4 mentions for ADMA Biologics. ADMA Biologics' average media sentiment score of 1.58 beat ANI Pharmaceuticals' score of 0.48 indicating that ADMA Biologics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
ANI Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
ADMA Biologics
3 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive

ADMA Biologics has a net margin of 45.01% compared to ANI Pharmaceuticals' net margin of -3.12%. ADMA Biologics' return on equity of 47.16% beat ANI Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
ANI Pharmaceuticals-3.12% 21.35% 7.52%
ADMA Biologics 45.01%47.16%30.51%

76.1% of ANI Pharmaceuticals shares are owned by institutional investors. Comparatively, 75.7% of ADMA Biologics shares are owned by institutional investors. 11.1% of ANI Pharmaceuticals shares are owned by company insiders. Comparatively, 3.5% of ADMA Biologics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

ADMA Biologics has lower revenue, but higher earnings than ANI Pharmaceuticals. ANI Pharmaceuticals is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ANI Pharmaceuticals$614.38M2.29-$18.52M-$1.27-51.15
ADMA Biologics$459.38M9.62$197.67M$0.8521.78

ANI Pharmaceuticals presently has a consensus target price of $78.88, suggesting a potential upside of 21.42%. ADMA Biologics has a consensus target price of $27.67, suggesting a potential upside of 49.47%. Given ADMA Biologics' stronger consensus rating and higher possible upside, analysts clearly believe ADMA Biologics is more favorable than ANI Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ANI Pharmaceuticals
0 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
3.00
ADMA Biologics
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
3.33

Summary

ADMA Biologics beats ANI Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

Get ANI Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for ANIP and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ANIP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ANIP vs. The Competition

MetricANI PharmaceuticalsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$1.43B$2.96B$5.62B$9.10B
Dividend YieldN/A2.39%5.24%4.00%
P/E Ratio-51.1520.8528.1820.27
Price / Sales2.29289.03428.7098.48
Price / Cash8.7042.8637.4658.16
Price / Book3.407.638.045.49
Net Income-$18.52M-$55.05M$3.19B$250.45M
7 Day Performance-0.51%8.43%3.62%4.79%
1 Month Performance4.57%5.42%4.06%7.68%
1 Year Performance2.30%2.03%30.00%16.43%

ANI Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ANIP
ANI Pharmaceuticals
3.6644 of 5 stars
$64.96
-1.7%
$78.88
+21.4%
+1.1%$1.43B$614.38M-51.15600News Coverage
Positive News
Analyst Forecast
Analyst Revision
ADMA
ADMA Biologics
3.9596 of 5 stars
$18.21
+0.3%
$27.67
+51.9%
+50.4%$4.34B$426.45M32.43530Positive News
ANVS
Annovis Bio
1.565 of 5 stars
$2.18
+6.3%
$30.25
+1,287.6%
-79.4%$39.95MN/A0.003
LNTH
Lantheus
4.5851 of 5 stars
$81.86
+0.5%
$130.50
+59.4%
-34.2%$5.64B$1.53B14.22700News Coverage
Positive News
TLX
Telix Pharmaceuticals
N/A$16.07
+0.4%
$22.00
+36.9%
N/A$5.41B$516.72M0.00N/ANews Coverage
Analyst Forecast
AXSM
Axsome Therapeutics
4.7407 of 5 stars
$104.39
+1.0%
$172.33
+65.1%
+28.9%$5.09B$385.69M0.00380Analyst Revision
AKRO
Akero Therapeutics
3.4071 of 5 stars
$53.36
-5.0%
$82.50
+54.6%
+107.6%$4.48BN/A0.0030Insider Trade
PCVX
Vaxcyte
1.8217 of 5 stars
$32.51
-0.2%
$136.50
+319.9%
-56.2%$4.20BN/A0.00160News Coverage
Positive News
KRYS
Krystal Biotech
4.6823 of 5 stars
$137.46
-1.0%
$211.13
+53.6%
-25.3%$4.01B$290.52M30.93210Trending News
Analyst Forecast
Insider Trade
Analyst Revision
RYTM
Rhythm Pharmaceuticals
3.1963 of 5 stars
$63.19
+0.7%
$77.31
+22.3%
+86.1%$3.99B$130.13M0.00140Trending News
Analyst Forecast
Insider Trade
Analyst Revision
CYTK
Cytokinetics
4.0782 of 5 stars
$33.04
-0.4%
$70.92
+114.7%
-34.3%$3.96B$18.47M-6.25250

Related Companies and Tools


This page (NASDAQ:ANIP) was last updated on 7/12/2025 by MarketBeat.com Staff
From Our Partners